BETA Q1 FY27 results at a glance
BETA DRUGS LIMITED Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹126 cr |
|---|
| Revenue YoY | +25.3% |
|---|
| Operating profit | ₹23.02 cr |
|---|
| Operating margin | 18.3% |
|---|
| Net profit | ₹15.8 cr |
|---|
| Net profit YoY | +35.1% |
|---|
| Net profit QoQ | +74.6% |
|---|
| Net margin | 12.6% |
|---|
| Basic EPS | ₹14.78 |
|---|
| TTM revenue | ₹410 cr |
|---|
| TTM net profit | ₹45.59 cr |
|---|
| TTM net margin | 11.1% |
|---|
BETA Q1 FY27 results: what the numbers say
BETA DRUGS LIMITED (BETA) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹126 cr and a net profit of ₹15.8 cr, translating into earnings per share of ₹14.78.
Compared with the same quarter a year earlier, revenue grew strongly by +25.3% and net profit grew strongly by +35.1%. Profit rising faster than revenue points to better cost control or operating leverage flowing through the P&L.
Operating profit for the quarter stood at ₹23.02 cr, an operating margin of 18.3% versus 15.9% a year ago — a gain of 2.4 percentage points.
BETA quarter-wise results table
Net profit
₹15.8 cr
+35.1% YoY
Operating profit
₹23.02 cr
+44.1% YoY
BETA DRUGS LIMITED (BETA) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹126 cr | ₹23.02 cr | ₹15.8 cr | 18.3% | 12.6% | ₹14.78 | +35.1% | +74.6% |
| Q4 FY262026-03-31 | ₹93.96 cr | ₹12.88 cr | ₹9.05 cr | 13.7% | 9.6% | ₹8.93 | — | +6.2% |
| Q3 FY262025-12-31 | ₹87.27 cr | ₹12.6 cr | ₹8.52 cr | 14.4% | 9.8% | ₹8.40 | — | -30.3% |
| Q2 FY262025-09-30 | ₹103 cr | ₹17.07 cr | ₹12.22 cr | 16.5% | 11.8% | — | — | +4.4% |
| Q1 FY262025-06-30 | ₹100 cr | ₹15.98 cr | ₹11.7 cr | 15.9% | 11.7% | ₹11.59 | — | — |
| TTM (last 4 quarters) | ₹410 cr | ₹65.57 cr | ₹45.59 cr | 16.0% | 11.1% | — | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
BETA quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
BETA DRUGS LIMITED quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹126 cr | ₹93.96 cr | ₹87.27 cr | ₹103 cr | ₹100 cr |
|---|
| Total expenses | ₹103 cr | ₹81.08 cr | ₹74.67 cr | ₹86.32 cr | ₹84.23 cr |
|---|
| Gross profit | ₹71.03 cr | ₹57.87 cr | ₹51.22 cr | ₹28.94 cr | ₹50.46 cr |
|---|
| Operating profit (EBIT) | ₹23.02 cr | ₹12.88 cr | ₹12.6 cr | ₹17.07 cr | ₹15.98 cr |
|---|
| Operating margin | 18.3% | 13.7% | 14.4% | 16.5% | 15.9% |
|---|
| Interest cost | ₹2.56 cr | ₹3.94 cr | ₹4.43 cr | ₹3.61 cr | ₹3.32 cr |
|---|
| Profit before tax | ₹22.04 cr | ₹11.83 cr | ₹10.47 cr | ₹16.44 cr | ₹15.65 cr |
|---|
| Tax expense | ₹5.56 cr | ₹2.78 cr | ₹1.95 cr | ₹4.23 cr | ₹3.95 cr |
|---|
| Effective tax rate | 25.2% | 23.5% | 18.7% | 25.7% | 25.2% |
|---|
| Net profit (PAT) | ₹15.8 cr | ₹9.05 cr | ₹8.52 cr | ₹12.22 cr | ₹11.7 cr |
|---|
| Net profit margin | 12.6% | 9.6% | 9.8% | 11.8% | 11.7% |
|---|
| Basic EPS | ₹14.78 | ₹8.93 | ₹8.40 | — | ₹11.59 |
|---|
| Diluted EPS | ₹14.78 | ₹8.93 | ₹8.40 | — | ₹11.59 |
|---|
BETA results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +25.3% | — | — | — | — |
|---|
| Revenue QoQ | +33.6% | +7.7% | -15.6% | +3.2% | — |
|---|
| Operating profit YoY | +44.1% | — | — | — | — |
|---|
| Operating profit QoQ | +78.7% | +2.3% | -26.2% | +6.8% | — |
|---|
| Net profit YoY | +35.1% | — | — | — | — |
|---|
| Net profit QoQ | +74.6% | +6.2% | -30.3% | +4.4% | — |
|---|
| EPS YoY | +27.5% | — | — | — | — |
|---|
| EPS QoQ | +65.5% | +6.3% | — | — | — |
|---|
BETA annual results history
Full-year performance for BETA DRUGS LIMITED, useful for reading each quarter in context.
BETA DRUGS LIMITED annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹385 cr | ₹362 cr | ₹296 cr | ₹227 cr |
|---|
| Total expenses | ₹326 cr | ₹300 cr | ₹246 cr | ₹184 cr |
|---|
| Gross profit | ₹214 cr | ₹191 cr | ₹115 cr | ₹97.61 cr |
|---|
| Operating profit (EBIT) | ₹58.53 cr | ₹62.09 cr | ₹50.13 cr | ₹43.03 cr |
|---|
| Operating margin | 15.2% | 17.1% | 17.0% | 18.9% |
|---|
| Interest cost | ₹15.31 cr | ₹6.99 cr | ₹2.68 cr | ₹2.28 cr |
|---|
| Profit before tax | ₹54.39 cr | ₹56.97 cr | ₹48.75 cr | ₹41.06 cr |
|---|
| Tax expense | ₹12.91 cr | ₹14.55 cr | ₹12.32 cr | ₹10.34 cr |
|---|
| Effective tax rate | 23.7% | 25.5% | 25.3% | 25.2% |
|---|
| Net profit (PAT) | ₹41.48 cr | ₹42.42 cr | ₹36.44 cr | ₹30.72 cr |
|---|
| Net profit margin | 10.8% | 11.7% | 12.3% | 13.5% |
|---|
| Basic EPS | ₹40.92 | ₹42.02 | ₹37.90 | ₹30.43 |
|---|
| Diluted EPS | ₹40.92 | ₹42.02 | ₹37.90 | ₹30.43 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹126 cr against ₹100 cr in Q1 FY26, and ₹93.96 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +33.6%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹103 cr, or 81.7% of revenue, with operating profit grew +44.1% year on year.
Margins, tax and profitability
Net profit of ₹15.8 cr works out to a net margin of 12.6% compared with 11.7% in the year-ago quarter. Margin expansion of this kind usually reflects a better product or service mix, softer input costs, or tighter overheads.
Below the operating line, BETA DRUGS LIMITED reported profit before tax of ₹22.04 cr, a tax charge of ₹5.56 cr (effective rate 25.2%), interest cost of ₹2.56 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹9.05 cr in Q4 FY26 to ₹15.8 cr in Q1 FY27, a change of +74.6%.
Trailing twelve months and annual context
Across the trailing four quarters BETA DRUGS LIMITED has generated revenue of ₹410 cr and net profit of ₹45.59 cr, a trailing net margin of 11.1%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹385 cr with net profit of ₹41.48 cr and EPS of ₹40.92, versus the prior year where revenue grew +6.2% and profit declined -2.2%.
What to watch in the next BETA quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
BETA DRUGS LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
BETA results coverage
No results report published for BETA yet — our desk covers each quarter within minutes of the filing.
BETA quarterly results FAQs
What were BETA DRUGS LIMITED (BETA) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), BETA DRUGS LIMITED reported revenue of ₹126 cr and net profit of ₹15.8 cr, a change of +35.1% year on year on +25.3% revenue growth. EPS stood at ₹14.78.
What is BETA profit margin in Q1 FY27?
BETA DRUGS LIMITED posted a net profit margin of 12.6% and an operating margin of 18.3% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹410 cr and net profit ₹45.59 cr.
Did BETA results beat the previous quarter?
BETA DRUGS LIMITED net profit changed +74.6% quarter on quarter, from ₹9.05 cr in Q4 FY26 to ₹15.8 cr in Q1 FY27.
When are BETA DRUGS LIMITED (BETA) quarterly results?
BETA DRUGS LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see BETA latest quarterly results?
Results coverage for BETA will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the BETA stock page.
What is BETA DRUGS LIMITED annual revenue and profit?
For FY26, BETA DRUGS LIMITED reported full-year revenue of ₹385 cr and net profit of ₹41.48 cr, with EPS of ₹40.92.
How many quarterly results has BETA declared recently?
Past results dates for BETA will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
